Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. Della Corte CM, et al. Among authors: gibson l. J Thorac Oncol. 2020 May;15(5):777-791. doi: 10.1016/j.jtho.2020.01.009. Epub 2020 Feb 15. J Thorac Oncol. 2020. PMID: 32068166 Free PMC article.
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Konen JM, et al. Among authors: gibson l. Cancer Res. 2021 Mar 1;81(5):1398-1412. doi: 10.1158/0008-5472.CAN-20-1895. Epub 2021 Jan 5. Cancer Res. 2021. PMID: 33402388 Free PMC article.
The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response.
Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsch DG, Creighton CJ, Gibbons DL. Kundu ST, et al. Among authors: gibson la. Genes Dev. 2022 May 1;36(9-10):582-600. doi: 10.1101/gad.349321.121. Epub 2022 Jun 2. Genes Dev. 2022. PMID: 35654454 Free PMC article.
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL. Rodriguez BL, et al. Among authors: gibson la. Front Immunol. 2023 Jun 28;14:1161869. doi: 10.3389/fimmu.2023.1161869. eCollection 2023. Front Immunol. 2023. PMID: 37449205 Free PMC article.
Anti-tumor activity of a novel LAIR1 antagonist in combination with anti-PD-1 to treat collagen-rich solid tumors.
Rodriguez BL, Huang J, Gibson L, Fradette JJ, Chen HH, Koyano K, Cortez C, Li B, Ho C, Ashique AM, Lin VY, Crawley S, Roda JM, Chen P, Fan B, Kim J, Sissons J, Sitrin J, Kaplan DD, Gibbons DL, Rivera LB. Rodriguez BL, et al. Among authors: gibson l. Mol Cancer Ther. 2024 Apr 22. doi: 10.1158/1535-7163.MCT-23-0866. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38648067
1,292 results